Benitec Biopharma Inc reports results for the quarter ended December 31 - Earnings Summary

• Benitec Biopharma Inc BNTC.OQ reported a quarterly adjusted loss of 33 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-2.64. The mean expectation of six analysts for the quarter was for a loss of 77 cents per share. Wall Street expected results to range from $-2.84 to -26 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Benitec Biopharma Inc's reported EPS for the quarter was a loss of 33 cents​.

• The company reported a quarterly loss of $7.36 million.

• Benitec Biopharma Inc shares had fallen by 23.2% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 24.7% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "strong buy"

Wall Street's median 12-month price target for Benitec Biopharma Inc is $28.00

This summary was machine generated from LSEG data February 18 at 12:54 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)